Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Phase of Trial: Phase II/III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms FINNjA-DM
- 23 May 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 26 Apr 2012 New source identified and integrated (European Clinical Trials Database record 2008-007667-17).
- 21 Jun 2011 Planned end date changed from Jul 2010 to Nov 2012 as reported by ClinicalTrials.gov.